

# Accepted Manuscript

Cardiovascular and cerebrovascular events among patients receiving omalizumab:  
Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-  
controlled clinical trials

Carlos Iribarren, MD, MPH, PhD, Kenneth J. Rothman, DrPH, Mary S. Bradley, MS,  
Gillis Carrigan, PhD, Mark D. Eisner, MD, Hubert Chen, MD, MPH

PII: S0091-6749(17)30040-4

DOI: [10.1016/j.jaci.2016.12.953](https://doi.org/10.1016/j.jaci.2016.12.953)

Reference: YMAI 12582

To appear in: *Journal of Allergy and Clinical Immunology*


Received Date: 17 February 2016

Revised Date: 10 November 2016

Accepted Date: 7 December 2016

Please cite this article as: Iribarren C, Rothman KJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials, *Journal of Allergy and Clinical Immunology* (2017), doi: 10.1016/j.jaci.2016.12.953.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Cardiovascular and cerebrovascular events among patients receiving**  
2 **omalizumab: Pooled analysis of patient-level data from 25 randomized, double-**  
3 **blind, placebo-controlled clinical trials**

4  
5 **Carlos Iribarren, MD, MPH, PhD,<sup>a</sup> Kenneth J. Rothman, DrPH,<sup>b</sup> Mary S. Bradley,**  
6 **MS,<sup>c\*</sup> Gillis Carrigan, PhD,<sup>c</sup> Mark D. Eisner, MD,<sup>c</sup> Hubert Chen, MD, MPH<sup>c</sup>**

7  
8 *<sup>a</sup>Division of Research, Kaiser Permanente Medical Care Program, Oakland, Calif,*  
9 *carlos.iribarren@kp.org; <sup>b</sup>RTI Health Solutions, Research Triangle Park, NC,*  
10 *krothman@rti.org; <sup>c</sup>Genentech, Inc., South San Francisco, Calif,*  
11 *bradley.mary@gene.com, carrigan.gillis@gene.com, esner.mark@gene.com,*  
12 *chen.hubert@gene.com*

13 \*Employee at the time of study

14  
15 Correspondence to: Hubert Chen, MD, MPH, 1 DNA Way, MS #453A, South San  
16 Francisco, CA 94080. E-mail: chenh37@gene.com. Tel: 650-225-4619. Fax: 650-467-  
17 2322.

18 **Role of the funding source**

19 This analysis was funded by Genentech, Inc., South San Francisco, Calif, and  
20 Novartis Pharma AG, Basel, Switzerland. Medical writing support for this manuscript  
21 was provided by Linda Goldstein, PhD, and Charlotte Kenreigh, PharmD, of Excel  
22 Scientific Solutions, Southport, Conn, and funded by Genentech, Inc. and Novartis  
23 Pharmaceuticals Corporation.

Download English Version:

<https://daneshyari.com/en/article/5646611>

Download Persian Version:

<https://daneshyari.com/article/5646611>

[Daneshyari.com](https://daneshyari.com)